Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction

Baseline characteristics and treatment of PARALLEL-HF trial

Hiroyuki Tsutsui, Shin Ichi Momomura, Yoshihiko Saito, Hiroshi Ito, Kazuhiro Yamamoto, Tomomi Ohishi, Naoko Okino, Toshihito Kitamura, Weinong Guo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The objective of the present analyses was to describe the baseline characteristics and treatment of the Japanese patients with HFrEF in THE PARALLEL-HF study. Methods and Results: Key demographic, clinical and laboratory findings, along with treatment, were reported and compared with patients enrolled in the PARADIGM-HF trial and other contemporary randomized clinical trials and registries of Japanese patients with HFrEF. In addition, the MAGGIC and EMPHASIS-HF risk scores were calculated. A total of 225 Japanese patients were randomized in PARALLEL-HF with a mean age of 67.9 years and the majority of the patients being male (85.8%) and in NYHA Class II (93.8%). Key baseline characteristics in PARALLEL-HF were generally comparable with PARADIGM-HF, and other contemporary clinical trials and registries of Japanese HFrEF patients. Patients enrolled in PARALLEL-HF were well treated with conventional evidence-based therapy at baseline (angiotensin-converting enzyme inhibitor inhibitor/angiotensin receptor blocker, 62.7%/37.3%; β-blockers, 94.7%; mineralocorticoid receptor antagonist, 59.1%). Despite the evidence-based treatment and most patients being in NYHA Class II, these patients had a low LVEF (mean 28.1%) and were at high risk of cardiovascular mortality and morbidity as assessed by the MAGGIC and EMPHASIS-HF risk scores. Conclusions: Overall, the patients in PARALLEL-HF were largely representative of contemporary ambulatory patients with HFrEF who are well treated with evidence-based therapies. PARALLEL-HF will determine whether sacubitril/valsartan provides similar improvements in clinical outcomes in Japanese HFrEF patients as observed in the PARADIGM-HF study.

Original languageEnglish
Pages (from-to)2575-2583
Number of pages9
JournalCirculation Journal
Volume82
Issue number10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Neprilysin
Angiotensin Receptors
Heart Failure
Therapeutics
Registries
Mineralocorticoid Receptor Antagonists
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction : Baseline characteristics and treatment of PARALLEL-HF trial. / Tsutsui, Hiroyuki; Momomura, Shin Ichi; Saito, Yoshihiko; Ito, Hiroshi; Yamamoto, Kazuhiro; Ohishi, Tomomi; Okino, Naoko; Kitamura, Toshihito; Guo, Weinong.

In: Circulation Journal, Vol. 82, No. 10, 01.01.2018, p. 2575-2583.

Research output: Contribution to journalArticle

Tsutsui, Hiroyuki ; Momomura, Shin Ichi ; Saito, Yoshihiko ; Ito, Hiroshi ; Yamamoto, Kazuhiro ; Ohishi, Tomomi ; Okino, Naoko ; Kitamura, Toshihito ; Guo, Weinong. / Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction : Baseline characteristics and treatment of PARALLEL-HF trial. In: Circulation Journal. 2018 ; Vol. 82, No. 10. pp. 2575-2583.
@article{1174a07f0e5945f793883a7ea258a0a2,
title = "Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction: Baseline characteristics and treatment of PARALLEL-HF trial",
abstract = "Background: The objective of the present analyses was to describe the baseline characteristics and treatment of the Japanese patients with HFrEF in THE PARALLEL-HF study. Methods and Results: Key demographic, clinical and laboratory findings, along with treatment, were reported and compared with patients enrolled in the PARADIGM-HF trial and other contemporary randomized clinical trials and registries of Japanese patients with HFrEF. In addition, the MAGGIC and EMPHASIS-HF risk scores were calculated. A total of 225 Japanese patients were randomized in PARALLEL-HF with a mean age of 67.9 years and the majority of the patients being male (85.8{\%}) and in NYHA Class II (93.8{\%}). Key baseline characteristics in PARALLEL-HF were generally comparable with PARADIGM-HF, and other contemporary clinical trials and registries of Japanese HFrEF patients. Patients enrolled in PARALLEL-HF were well treated with conventional evidence-based therapy at baseline (angiotensin-converting enzyme inhibitor inhibitor/angiotensin receptor blocker, 62.7{\%}/37.3{\%}; β-blockers, 94.7{\%}; mineralocorticoid receptor antagonist, 59.1{\%}). Despite the evidence-based treatment and most patients being in NYHA Class II, these patients had a low LVEF (mean 28.1{\%}) and were at high risk of cardiovascular mortality and morbidity as assessed by the MAGGIC and EMPHASIS-HF risk scores. Conclusions: Overall, the patients in PARALLEL-HF were largely representative of contemporary ambulatory patients with HFrEF who are well treated with evidence-based therapies. PARALLEL-HF will determine whether sacubitril/valsartan provides similar improvements in clinical outcomes in Japanese HFrEF patients as observed in the PARADIGM-HF study.",
author = "Hiroyuki Tsutsui and Momomura, {Shin Ichi} and Yoshihiko Saito and Hiroshi Ito and Kazuhiro Yamamoto and Tomomi Ohishi and Naoko Okino and Toshihito Kitamura and Weinong Guo",
year = "2018",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-17-1424",
language = "English",
volume = "82",
pages = "2575--2583",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

TY - JOUR

T1 - Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction

T2 - Baseline characteristics and treatment of PARALLEL-HF trial

AU - Tsutsui, Hiroyuki

AU - Momomura, Shin Ichi

AU - Saito, Yoshihiko

AU - Ito, Hiroshi

AU - Yamamoto, Kazuhiro

AU - Ohishi, Tomomi

AU - Okino, Naoko

AU - Kitamura, Toshihito

AU - Guo, Weinong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The objective of the present analyses was to describe the baseline characteristics and treatment of the Japanese patients with HFrEF in THE PARALLEL-HF study. Methods and Results: Key demographic, clinical and laboratory findings, along with treatment, were reported and compared with patients enrolled in the PARADIGM-HF trial and other contemporary randomized clinical trials and registries of Japanese patients with HFrEF. In addition, the MAGGIC and EMPHASIS-HF risk scores were calculated. A total of 225 Japanese patients were randomized in PARALLEL-HF with a mean age of 67.9 years and the majority of the patients being male (85.8%) and in NYHA Class II (93.8%). Key baseline characteristics in PARALLEL-HF were generally comparable with PARADIGM-HF, and other contemporary clinical trials and registries of Japanese HFrEF patients. Patients enrolled in PARALLEL-HF were well treated with conventional evidence-based therapy at baseline (angiotensin-converting enzyme inhibitor inhibitor/angiotensin receptor blocker, 62.7%/37.3%; β-blockers, 94.7%; mineralocorticoid receptor antagonist, 59.1%). Despite the evidence-based treatment and most patients being in NYHA Class II, these patients had a low LVEF (mean 28.1%) and were at high risk of cardiovascular mortality and morbidity as assessed by the MAGGIC and EMPHASIS-HF risk scores. Conclusions: Overall, the patients in PARALLEL-HF were largely representative of contemporary ambulatory patients with HFrEF who are well treated with evidence-based therapies. PARALLEL-HF will determine whether sacubitril/valsartan provides similar improvements in clinical outcomes in Japanese HFrEF patients as observed in the PARADIGM-HF study.

AB - Background: The objective of the present analyses was to describe the baseline characteristics and treatment of the Japanese patients with HFrEF in THE PARALLEL-HF study. Methods and Results: Key demographic, clinical and laboratory findings, along with treatment, were reported and compared with patients enrolled in the PARADIGM-HF trial and other contemporary randomized clinical trials and registries of Japanese patients with HFrEF. In addition, the MAGGIC and EMPHASIS-HF risk scores were calculated. A total of 225 Japanese patients were randomized in PARALLEL-HF with a mean age of 67.9 years and the majority of the patients being male (85.8%) and in NYHA Class II (93.8%). Key baseline characteristics in PARALLEL-HF were generally comparable with PARADIGM-HF, and other contemporary clinical trials and registries of Japanese HFrEF patients. Patients enrolled in PARALLEL-HF were well treated with conventional evidence-based therapy at baseline (angiotensin-converting enzyme inhibitor inhibitor/angiotensin receptor blocker, 62.7%/37.3%; β-blockers, 94.7%; mineralocorticoid receptor antagonist, 59.1%). Despite the evidence-based treatment and most patients being in NYHA Class II, these patients had a low LVEF (mean 28.1%) and were at high risk of cardiovascular mortality and morbidity as assessed by the MAGGIC and EMPHASIS-HF risk scores. Conclusions: Overall, the patients in PARALLEL-HF were largely representative of contemporary ambulatory patients with HFrEF who are well treated with evidence-based therapies. PARALLEL-HF will determine whether sacubitril/valsartan provides similar improvements in clinical outcomes in Japanese HFrEF patients as observed in the PARADIGM-HF study.

UR - http://www.scopus.com/inward/record.url?scp=85054095950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054095950&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-17-1424

DO - 10.1253/circj.CJ-17-1424

M3 - Article

VL - 82

SP - 2575

EP - 2583

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -